drugset / Trial / NCT01584206

Sitosterolemia Metabolism

NCT01584206

Completed 8 enrolled University of Manitoba
NaSingle-groupOpen-labelBasic science

Summary

Ezetimibe has become the treatment choice for patients with sitosterolemia. Ezetimibe is an inhibitor of cholesterol absorption from the gastrointestinal tract. The purpose of this study is to determine if ezetimibe improves whole body plant sterol and cholesterol homeostasis.

Timeline

Start
2012-04
Primary completion
2013-08
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg

Indications